Browsing by Author "Kuyucu, Necdet"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Clinical and epidemiological features of Turkish children with 2009 pandemic influenza A (H1N1) infection: Experience from multiple tertiary paediatric centres in Turkey
    (Informa Healthcare, 2011-12) Çiftçi, Ergin; Tuygun, Nilden; Özdemir, Halil; Tezer, Hasan; Şensoy, Gülnar; Devrim, İlker; Dalgıç, Nazan; Kara, Ateş; Turgut, Mehmet; Tapısız, Anıl; Keser, Melike; Bayram, Nuri; Kocabaş, Emine; Dinleyici, Ener Çağrı; Özen, Metehan; Soysal, Ahmet; Kuyucu, Necdet; Tanır, Gönül; Çelikel, Elif; Belet, Nursen; Evren, Gültaç; Aytaç, Didem Büyüktaş; Cengiz, Ali Bülent; Canoz, Perihan Yasemen; Derinoz, Oksan; İnce, Erdal; Hacımustafaoğlu, Mustafa; Anıl, Murat; Özgür, Özlem; Kuzdan, Canan; Özaydin, Eda; Aşılıoğlu, Nazik; Dizdarer, Ceyhun; Ceyhan, Mehmet; Bucak, İbrahim Hakan; Kendirli, Tanıl; Yakut, Halil İbrahim; Fisgin, Tunç; Unal, Nurettin; Altındağ, Hakan; Kılınç, Ayse Ayzit; Zohre, Seray Umut; Elhan, Atilla Halil; Doğru, Ülker; Çelebi, Solmaz; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.; 7006095295
    Background: In April 2009 a novel strain of human influenza A, identified as H1N1 virus, rapidly spread worldwide, and in early June 2009 the World Health Organization raised the pandemic alert level to phase 6. Herein we present the largest series of children who were hospitalized due to pandemic H1N1 infection in Turkey. Methods: We conducted a retrospective multicentre analysis of case records involving children hospitalized with influenza-like illness, in whom 2009 H1N1 influenza was diagnosed by reverse-transcriptase polymerase chain reaction assay, at 17 different tertiary hospitals. Results: A total of 821 children with 2009 pandemic H1N1 were hospitalized. The majority of admitted children (56.9%) were younger than 5 y of age. Three hundred and seventy-six children (45.8%) had 1 or more pre-existing conditions. Respiratory complications including wheezing, pneumonia, pneumothorax, pneumomediastinum, and hypoxemia were seen in 272 (33.2%) children. Ninety of the patients (11.0%) were admitted or transferred to the paediatric intensive care units (PICU) and 52 (6.3%) received mechanical ventilation. Thirty-five children (4.3%) died. The mortality rate did not differ between age groups. Of the patients who died, 25.7% were healthy before the H1N1 virus infection. However, the death rate was significantly higher in patients with malignancy, chronic neurological disease, immunosuppressive therapy, at least 1 pre-existing condition, and respiratory complications. The most common causes of mortality were pneumonia and sepsis. Conclusions: In Turkey, 2009 H1N1 infection caused high mortality and PICU admission due to severe respiratory illness and complications, especially in children with an underlying condition.
  • No Thumbnail Available
    Publication
    Clinical practical recommendations for Turkish national vaccination schedule for previously healthy children (national vaccination schedule) and vaccines not included in the schedule - 2015
    (Aves Yayincilik, Ibrahim Kara, 2015-03-01) Arısoy, Emin Sami; Çiftiç, Ergin; Hacımustafaoğlu, Mustafa; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Kara, Ateş; Kuyucu, Necdet; Somer, Ayper; Vardar, Fadıl; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.; 0000-0003-4646-660X; 0000-0002-1654-3232; 0000-0002-6721-4105; I-9081-2013; H-3094-2018; W-2756-2017; AAE-5459-2020
  • No Thumbnail Available
    Item
    Comparison of two different regimens of combined interferon-alpha 2a and lamivudine therapy in children with chronic hepatitis B infection
    (Int Medical Press, 2006) Kansu, A.; Doğancı, Tumay; Akman, Sezın; Artan, Reha; Kuyucu, Necdet; Kalaycı, Ayhan Gazi; Dikici, Bünyamin; Dalgiç, Buket; Selimoğlu, Ayşe; Erhun, Kasırga; Zarife, Kuloğlu; Aydoğdu, Sema; Boşnak, Mehmet; Ertekin, Vildan; Tanır, Gönül; Haspolat, Kenan; Girgin, Nurten; Yağcı, Raşit Vural; Özkan, Tanju B.; Uludağ Üniversitesi/Tıp Fakültesi/Pediatrik Gastroenteroloji, Hepatoloji ve Beslenme Anabilim Dalı.; 7004474005
    Aim: To evaluate the efficacy of two regimens of combined interferon-alpha 2a (IFN-alpha 2a) and lamivudine (3TC) therapy in childhood chronic hepatitis B. Methods: A total of 177 patients received IFN-alpha 2a, 9 million units (MU)/m(2) for 6 months. In group 1 (112 patients, 8.7 +/- 3.5 years), 3TC (4 mg/kg/day, max 100 mg) was started simultaneously with IFN-alpha 2a, in group 11 (65 patients, 9.6 +/- 3.8 years) 3TC was started 2 months prior to IFN-alpha 2a. 3TC was continued for 6 months after antiHBe seroconversion or stopped at 24 months in non-responders. Results: Baseline alanine aminotransferase (ALT) was 134.2 +/- 34.1 and 147.0 +/- 45.3; histological activity index (HAI) was 7.4 +/- 2.7 and 7.1 +/- 2.3; and HBV DNA levels were above 2,000 pg/ml in 76% and 66% of patients in groups I and 11, respectively (P > 0.005). Complete response was 55.3% and 27.6% in groups I and 11, respectively (P < 0.01). AntiHBe seroconversion was higher and earlier, and HBV DNA clearance was earlier in group I (P < 0.05). HBsAg clearance was 12.5% and 4.6% and antiHBs seroconversion was 9.8% and 6.2% in groups I and 11, respectively (P > 0.05). Breakthrough occurred in 17.9% and 24.6%; breakthrough times were 15.9 +/- 4.6 and 14.1 +/- 5.1 months; and relapse rates were 6.8% and none in groups I and 11, respectively (P > 0.05, P > 0.05, P > 0.05). Responders had higher HAI (HAI > 6) and higher pre-treatment ALT than non-responders. Conclusion: Simultaneous 3TC+IFN-alpha 2a yields a higher response and earlier antiHBe seroconversion and viral clearance than consecutive combined therapy. Relapse rate is low. Predictors of response are high basal ALT and high HAI scores. 3TC can be administered for 24 months without any side effect and breakthrough rate is comparable with previous studies.
  • Thumbnail Image
    Publication
    The national vaccination schedule in previously healthy children: The practical recommendations about additional vaccines
    (Aves Yayıncılık, 2014-03-01) Arısoy, Emin Sami; Ceyhan, Mehmet; Çiftci, Ergin; Hacımustafaoğlu, Mustafa; Kara, Ateş; Kuyucu, Necdet; Somer, Ayper; Vardar, Fadıl; Arısoy, Emin Sami; Ceyhan, Mehmet; Çiftci, Ergin; HACIMUSTAFAOĞLU, MUSTAFA KEMAL; Kara, Ateş; Kuyucu, Necdet; Somer, Ayper; Vardar, Fadıl; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.; 0000-0003-2839-2547; 0000-0003-4646-660X; 0000-0002-1654-3232; 0000-0002-6721-4105; H-3094-2018; EQC-2857-2022; W-2756-2017; CTG-5805-2022; I-9081-2013; FGO-7019-2022; AAE-5459-2020; CGC-3104-2022